209 related articles for article (PubMed ID: 25933185)
1. Pancreatic cancer, treatment options, and GI-4000.
Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
Hum Vaccin Immunother; 2015; 11(4):931-7. PubMed ID: 25933185
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer, treatment options, and GI-4000.
Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
Hum Vaccin Immunother; 2014; 10(11):3347-53. PubMed ID: 25585100
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
4. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Boeck S; Jung A; Laubender RP; Neumann J; Egg R; Goritschan C; Vehling-Kaiser U; Winkelmann C; Fischer von Weikersthal L; Clemens MR; Gauler TC; Märten A; Klein S; Kojouharoff G; Barner M; Geissler M; Greten TF; Mansmann U; Kirchner T; Heinemann V
Br J Cancer; 2013 Feb; 108(2):469-76. PubMed ID: 23169292
[TBL] [Abstract][Full Text] [Related]
5. New biomarkers and targets in pancreatic cancer and their application to treatment.
Costello E; Greenhalf W; Neoptolemos JP
Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):435-44. PubMed ID: 22733351
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Fensterer H; Schade-Brittinger C; Müller HH; Tebbe S; Fass J; Lindig U; Settmacher U; Schmidt WE; Märten A; Ebert MP; Kornmann M; Hofheinz R; Endlicher E; Brendel C; Barth PJ; Bartsch DK; Michl P; Gress TM;
Ann Oncol; 2013 Oct; 24(10):2576-2581. PubMed ID: 23897705
[TBL] [Abstract][Full Text] [Related]
7. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Baechmann S; Ormanns S; Haas M; Kruger S; Remold A; Modest DP; Kirchner T; Jung A; Werner J; Heinemann V; Boeck S
BMC Cancer; 2017 May; 17(1):374. PubMed ID: 28549417
[TBL] [Abstract][Full Text] [Related]
8. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Strimpakos AS; Saif MW
JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
[TBL] [Abstract][Full Text] [Related]
9. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.
Réjiba S; Wack S; Aprahamian M; Hajri A
Cancer Sci; 2007 Jul; 98(7):1128-36. PubMed ID: 17489984
[TBL] [Abstract][Full Text] [Related]
10. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
Ocal O; Pashkov V; Kollipara RK; Zolghadri Y; Cruz VH; Hale MA; Heath BR; Artyukhin AB; Christie AL; Tsoulfas P; Lorens JB; Swift GH; Brekken RA; Wilkie TM
Dis Model Mech; 2015 Oct; 8(10):1201-11. PubMed ID: 26438693
[TBL] [Abstract][Full Text] [Related]
11. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
[TBL] [Abstract][Full Text] [Related]
12. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Golan T; Khvalevsky EZ; Hubert A; Gabai RM; Hen N; Segal A; Domb A; Harari G; David EB; Raskin S; Goldes Y; Goldin E; Eliakim R; Lahav M; Kopleman Y; Dancour A; Shemi A; Galun E
Oncotarget; 2015 Sep; 6(27):24560-70. PubMed ID: 26009994
[TBL] [Abstract][Full Text] [Related]
13. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
da Cunha Santos G; Dhani N; Tu D; Chin K; Ludkovski O; Kamel-Reid S; Squire J; Parulekar W; Moore MJ; Tsao MS
Cancer; 2010 Dec; 116(24):5599-607. PubMed ID: 20824720
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Expert Rev Anticancer Ther; 2002 Aug; 2(4):426-36. PubMed ID: 12647986
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Kim HS; Kim JI; Jeong M; Seo JH; Kim IK; Cheung DY; Kim TJ; Kang CS
World J Gastroenterol; 2014 Sep; 20(35):12682-6. PubMed ID: 25253976
[TBL] [Abstract][Full Text] [Related]
16. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
17. Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer.
Ryu WJ; Han G; Lee SH; Choi KY
Biochem Biophys Res Commun; 2021 Apr; 549():40-46. PubMed ID: 33662667
[TBL] [Abstract][Full Text] [Related]
18. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
19. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
Grey A; Cooper A; McNeil C; O'Toole S; Thompson J; Grimison P
Intern Med J; 2014 Jun; 44(6):597-600. PubMed ID: 24946815
[TBL] [Abstract][Full Text] [Related]
20. Selecting chemotherapy for pancreatic cancer: Far away or so close?
Shi S; Yu X
Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
